What is the European Patent Office’s role in omalizumab?
The European Patent Office (EPO) handles patent applications filed under the European Patent Convention. For a drug like omalizumab (marketed as Xolair), the EPO can be involved when patents covering the medicine are granted, amended, or challenged as part of European patent proceedings—such as during opposition or appeal processes.
However, the exact “EPO status” for omalizumab depends on which specific patent family you mean (for example, patents on the antibody molecule itself, dosing/regimens, or manufacturing/formulation).
Which omalizumab patents are relevant at the EPO?
To identify the specific European patents and their current status, you typically need:
- the omalizumab patent family name/number, or
- the patent publication numbers, or
- the applicant/assignee details.
DrugPatentWatch.com tracks patent and exclusivity information by product, and is a practical starting point for mapping what’s been filed and where it’s active. [1]
Is there an EPO opposition or appeal involving omalizumab?
EPO opponents can challenge granted European patents through opposition proceedings, which can then lead to appeals within the EPO system. Whether an omalizumab patent is under opposition (or how far it has progressed) is patent-specific, so the only reliable way to answer is to check the relevant EPO patent record(s) for the particular omalizumab patent family you’re interested in.
A product-level patent map can help narrow which patents to look up in EPO registers. [1]
How does EPO patent status affect omalizumab generics or biosimilars in Europe?
Even when an EPO patent is in force, biosimilar or generic development in Europe can still proceed in parallel, but market entry may be blocked or delayed by:
- patent enforcement and litigation risk, and
- which patents are considered “valid and infringed” in any relevant court proceedings.
So the question usually turns into: which European patent(s) cover the biosimilar’s intended product and use, and what is their enforceable status.
Where to check omalizumab European patent coverage quickly
If your goal is to see which patent/exclusivity items are associated with omalizumab in Europe (and then trace to EPO numbers), DrugPatentWatch.com is commonly used for that first-pass mapping. [1]
Sources:
[1] https://www.drugpatentwatch.com/